Exco InTouch Predicts Strong Growth in Mobile ePRO Release
Exco InTouch, a leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, predicts ever increasing uptake of mobile electronic patient reported outcomes (ePRO) due to the multiple benefits that it brings to the market.
Electronic data collection has grown rapidly over the course of the last 10 years and has already emerged as a common asset in clinical research for the completion of Clinical Outcome Assessments (COA), including the outcomes captured directly from patients; patient reported outcomes (PRO). The global growth of mobile technology has provided a new and efficient method of accessing patients, creating an ideal platform for capturing ePRO assessments.
Mobile eCOA has brought a plethora of benefits to clinical studies. In addition to supporting diaries and questionnaires, native apps have proven a highly useful resource for facilitating the collection of objective data from medical devices, such as spirometers and glucometers, and wearable technology including activity trackers, alongside patient diaries. Data from these devices, transmitted directly into an app via Bluetooth, enables the collection of physiological data without the need for the patient to complete a site visit or the requirement to transcribe results manually.
Mobile eCOA can also boost patient engagement through the use of a simple, yet familiar interface supported by motivational messages, alerts, reminders and educational materials as appropriate for each study. Additionally, alerts can be raised to sites to highlight missed entries, enabling them to contact patients and discuss any difficulties or misunderstandings before the patient is lost to follow up.
Furthermore, mobile offers a safe and secure method of collecting patient data, protecting confidentiality in ePRO through the introduction of unique PINs created by the users. Both data transmission and offline storage is secured through data encryption. Data accessibility enables real-time access to PRO data by sites and sponsor teams through reports and metrics, providing comprehensive oversight to both individual and merged data.
Electronic data collection provides the benefit of being applicable through either the BYOD (Bring Your Own Device) approach or through provisioning devices. Adoption of the BYOD approach to collect eCOA data, which has been used in late phase post approval studies for some time, is now becoming increasingly used in Phase II & III clinical trials. Moreover, the use of apps simplifies device management, for example, by enabling remote deployment of interim study updates, without any need to recall patients and their devices back to sites.
As ePRO has become more embedded as a tool for clinical data capture, many PRO instruments that are widely accepted in paper formats have been adapted into ePRO versions. Since the manual, paper-based process for collecting PROs may not only be cost- and time-inefficient, but also unreliable, mobile devices will play an ever increasing role in the accumulation of patient endpoint data due to its ease of accessibility and cost- and time-efficiency.
Tim Davis, CEO and Founder of Exco InTouch, commented: “Mobile eCOA has proved to be highly beneficial and versatile for use in clinical trials, significantly improving the efficiency of studies and the quality of patient reported outcomes. It is set for further expansion and growth as the industry escalates the adoption of existing mobile PRO as the standard approach to self-reported clinical data.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance